Straits Times Index
3,246.33 -13.70 (-0.42%) Nikkei
26,717.34 +547.04 (+2.09%) Hang Seng
23,550.08 -256.92 (-1.08%) FTSE 100
7,466.07 -88.24 (-1.17%) BTC-USD
37,825.68 +1,210.10 (+3.30%) CMC Crypto 200
863.83 +21.37 (+2.54%)
Marpai, Inc. (MRAI)
After hours:
| Previous close | 1.9700 |
| Open | 1.9700 |
| Bid | 2.0800 x 1400 |
| Ask | 2.1400 x 1000 |
| Day's range | 1.8200 - 2.1650 |
| 52-week range | 1.8200 - 6.3100 |
| Volume | |
| Avg. volume | 1,617,322 |
| Market cap | 43.545M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.6940 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
- Business Wire
Marpai, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
TAMPA, Fla., January 07, 2022--Marpai, Inc. (NASDAQ: MRAI), a deep learning technology company transforming third party administration in the self-funded health insurance market, today announced that an interview with CEO Edmundo Gonzalez will air on The RedChip Money Report® on Bloomberg TV on Saturday, Jan. 8 at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.
- Business Wire
Marpai, Inc. Insiders Buy $1.1 Million of Common Stock
NEW YORK, December 20, 2021--Marpai, Inc. ("Marpai" or the "Company") (NASDAQ: MRAI), a deep learning technology company transforming third party administration (TPA) in the self-funded health insurance market, today announced the Company’s management and directors purchased $1.1 million of Marpai common stock.
- Business Wire
Marpai, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
TAMPA, Fla., October 29, 2021--Marpai, Inc. (the "Company") (Nasdaq: MRAI), a deep learning technology company transforming third party administration in the healthcare self-funded market, today announced the closing of its initial public offering of 7,187,500 shares of its common stock at a public offering price of $4.00 per share, including 937,500 shares sold upon full exercise of the underwriters’ over-allotment option, for gross proceeds of $28.75 million, before deducting underwriting disc
